InvestorsHub Logo
Followers 62
Posts 7557
Boards Moderated 1
Alias Born 01/02/2003

Re: CaptBeer post# 414663

Sunday, 08/27/2023 8:26:35 PM

Sunday, August 27, 2023 8:26:35 PM

Post# of 426487
I blame Dr. Nissen...He knew better, and had no reason to spout out all the nonsense that he did about the MO placebo in the R-IT study being the reason for the success of Amarin's R-IT study....

Except that Nissen had previously advised to AZ to buy Omacor(which contained DHA as well as EPA), for an large amount of cash, as a potential competitor to Vascepa...and then Nissen convinced AZ to do very expensive studies on Omacor...

When AZ ultimately turned out to be an expensive and an embarrassing failure, it did great harm to Nissen's reputation...

After this very embarrassing episode, Nissen blamed Amarin because it had done a very successful R-IT study on Vascepa....This episode has seriously hurt Nissen's reputation as a medical wizard, inducing him to continuously discredit Vascepa by implying that Vascepa would have also failed, as did Omacor, except for the R-IT MO placebo making the R-It study make Vascepa look superior to Omacor on reducing CVD...

Nessen's argument concerning the importance of the negative effects from the small quantities of MO used in the R-IT study placebo study, has been conclusively proven to be false.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News